DENVER, Colo., Nov 25, 2025 (247marketnews.com)- Below is your Power Hour rundown, the catalysts shaping sentiment right now and the names to keep on screen into the close.
Kraig Biocraft Laboratories (OTCQB:KBLB): Scaling Up and Staffing Up
Kraig Biocraft Laboratories continues to generate buzz as its hiring wave accelerates. The company is rapidly expanding its Southeast Asia production workforce to support rising spider silk throughput and the development of a new manufacturing center.
New hires will train under sericulture authority Dr. Nirmal Kumar, underscoring just how aggressively KBLB is preparing for industrial-scale output. CEO Kim Thompson pointed to the company’s “forward-looking production strategy” as construction progresses. With attention growing around sustainable materials and advanced fibers, KBLB is emerging as a speculative favorite heading into the close.
PharmaCyte Biotech (NASDAQ:PMCB): Cash-Rich and Reinforcing Its Strategy
PharmaCyte Biotech turned heads this morning with confirmation that it successfully monetized its stake in Femasys (NASDAQ:FEMY), boosting its expected cash and securities position to roughly $45 million, including about $20 million in cash and $25 million in marketable securities.
CEO Josh Silverman said the move highlights the company’s “strategic and disciplined capital allocation approach,” and with PMCB trading near $0.65 despite this strengthened position, value investors are circling. With only 6.8 million shares outstanding, PMCB becomes a tightly held, cash-heavy biotech name to watch into afterhours.
Rubico (NASDAQ:RUBI): Multi-Year Revenue Visibility Locks In
Rubico delivered one of the day’s clearest long-term signals: both of its ECO tanker vessels locked in extended charters, guaranteeing premium hire rates through 2027 and beyond. The move pushes RUBI’s contracted revenue backlog to $120.8 million, a material figure given its compact fleet size.
In a tanker market driven by energy route dislocations and fleet scarcity, RUBI’s multi-year visibility stands out. Momentum traders are watching for volume spikes as the session winds down.
Symbotic (NASDAQ:SYM): Automation Powerhouse Posts a Strong Year
Symbotic’s fiscal 2025 earnings continue to ripple through the market. Q4 revenue hit $618 million, with full-year sales climbing 26% to $2.247 billion. While SYM reported a net loss, the company’s cash surged to $1.245 billion, and adjusted EBITDA expanded meaningfully.
CEO Rick Cohen highlighted strong margin performance and new vertical expansion, including a new footprint in healthcare logistics. Guidance for Q1 FY2026 (revenue of $610M–$630M) helps stabilize sentiment around one of the market’s purest AI-meets-automation plays.
OSR Holdings (NASDAQ:OSRH): Vaximm Inks Term Sheet for a Potential $835M+ Licensing Deal
Last week’s announcement from OSR Holdings continues to reverberate today as investors parse the implications of Vaximm AG’s non-binding term sheet with BCM Europe AG for potential licensing of VXM01, its oral T-cell cancer immunotherapy platform.
The contemplated structure includes:
- $20 million upfront
- Up to $815 million in milestones
- A royalty pass-through model with BCME acting as a strategic intermediary
Incoming Vaximm CEO Andreas Niethammer said the collaboration would “accelerate development and global commercialization,” while OSRH’s IR head Tim Smith noted the shared commitment to maximizing VXM01’s global opportunity. Layer in the optional blockchain-based royalty participation mechanism, and OSRH becomes one of today’s more structurally innovative biotech stories.
Esperion Therapeutics (NASDAQ:ESPR): Analyst Coverage Sparks Speculation
Analyst activity is stirring interest after Piper Sandler initiated coverage with an Overweight rating and a $9 price target. With cardiovascular drug developers drawing renewed investor focus, fresh analyst attention, especially from a major shop, often brings incremental volume through the bell.
For more information about Kraig Labs’ spider silk technology and partnership opportunities, visit www.kraiglabs.com
Please click here to read the full Kraig Labs analyst report on 247marketnews.com.
For more information, please visit: www.kraiglabs.com
Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247 is a third-party media provider and has been compensated for providing ongoing KBLB market outreach and other services. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. Please review 247’s Full Disclaimer https://www.247marketnews.com/disclaimer/. Please go to https://247marketnews.com/kblb-disclosure/ for further KBLB and 247marketnews.com disclosure information.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
The post Deal-Making, Cash Stacking, and Sector Shakeups Put These Names on Watch into the Close appeared first on 24/7 MarketNews.